The phase 2 trial is led by principal investigator Matthew Rizzo, MD, according to a March 14 news release. Dr. Rizzo currently serves as the Reynolds Professor and Chair of the UNMC Department of Neurological Sciences.
The trial aims to enroll 180 participants to evaluate the effectiveness of Nantheia ATL5, a drug using cannabidiol in ANANDA’s proprietary Liquid Structure delivery technology to treat PTSD.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.